China-focused CASI Pharmaceuticals gets Marqbio review by CFDA

China-focused and Nasdaq-listed biotech CASI Pharmaceuticals ($CASI) said Marqbio, an oncology drug, was accepted for import registration review by the China FDA. The company licensed Marqbio China rights from Spectrum Pharmaceuticals ($SPPI) in a 2014 deal covering two oncology therapies. "Marqbio is the first and only liposome-encapsulated vincristine approved and currently marketed in the U.S. for second line treatment of adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)," the company said in a release. The company said the review process is expected to include a confirmatory trial in China. In September of last year, CASI raised $25 million in a secondary offering with the funds earmarked for clinical trials. Release

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.